We are currently examining the activated levels of Akt and Erk in MM patient cells to evaluate if these could serve as biomarkers to predict for sensitivity to MK-2206 and other PI3K/Akt/mTOR inhibitors. This evidence concerns the gene AKT1 and Miyoshi myopathy.